Antriabio – which trades under the ticker “ANTB” – is about to bounce. If you’ve been following what I have to say I also think ANTB has 10-bagger potential (more about that in a moment).
According to otcshortreport.com, about 50% of the shares that have traded in the last 30 days were sold short. A friend of mine who specializes in reverse-mergers and IPOs explained that market makers will short almost every new listing without regard for the (a) valuation, or (b) quality of the company. This is the only logical explanation I could muster in line with the short interest, since finding a “borrow” (which is what you need to short a stock) is IMPOSSIBLE with this name. My friend also explained that once a company gains visibility with traders and investors (or “the market”), market makers will cover their short positions. Of course a sharp or sudden move in the stock helps spark covering also.
The takeaway here is that short-selling by market makers is real and does in fact contribute to a “squeeze”. I would not expect to see a squeeze of epic proportions but I would not be surprised if ANTB were to gain momentum on a news announcement or technical breakout in the next few days and weeks.
To that I want to add: ANTB is a REAL technology, a company with a superior long-acting insulin analogue product-candidate. Basil insulin products bring in more than $8 BILLION dollars in revenue to drug makers every year (and growing). Their technology allows people with diabetes to control blood sugar levels with a weekly injection of insulin as opposed to having to take a shot every day. This isn’t (perhaps) as exciting as 3-D printing but has HUGE implications and HUGE revenue potential, including:
- potential for a MASSIVE partnership,
- licensing deal, or
- outright ACQUISITION
If you read this press release announcing new appointments to ANTB’s management team, you’ll notice that both the new CEO and Chief Scientific Officer – or CSO – sold companies to big pharma for hundreds of millions of dollars.
Diabetes will be one of the hottest spaces to invest in over the next decade, undisputed. ANTB, in my opinion, will be one of the best diabetes plays this year. I think there’s 10-bagger potential here in 2013, but equally, as mentioned, see a bounce trade opportunity in the short term.
Watch for a bounce in ANTB stock.
An affiliate of PennyStockHaven.com received twenty thousand dollars per month for providing consulting and advisory services to AntriaBio in the past and may receive cash and/or restricted stock in the future. This compensation may affect the objectivity of our profile of the company. PennyStockHaven.com own shares acquired in the open market and may sell these shares at any time. You should do your own homework and consult an investment professional before making any investment decisions. Read our full disclaimer here.